Novartis plans to close a Sandoz generics manufacturing facility in Broomfield, CO that will result in the loss of approximately 450 jobs over the next couple of years. The company plans to discontinue and/or divest several products with limited growth potential, specifically those facing pricing pressures in the U.S.
 
The products include oral generic treatments in cardiology, central nervous system, endocrinology, respiratory and pain. 
 
The phased closure and transfer of some operations to a Sandoz facility in North Carolina is scheduled to be completed in late 2019.